Muscle-invasive and Metastatic Bladder Cancer
Éva Compérat(Vienna General Hospital), Erik Veskimäe(Tampere University), Thierry Lebrét(Université de Versailles Saint-Quentin-en-Yvelines), Estefanía Linares(Hospital Universitario La Paz), Max Bruins(Radboud University Nijmegen), Maria De Santis(Medical University of Vienna), Virginia Hernández(Hospital Universitario Fundación Alcorcón), Georgios Gakis(University Hospital in Halle), Mathieu Rouanne(Université de Versailles Saint-Quentin-en-Yvelines), James Dunn(Stanford University), Y. Neuzillet(Université de Versailles Saint-Quentin-en-Yvelines)
Unknown
January 1, 2016
Cited by 15
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
|European Urology|2016|1.5k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694